Clinical studies with misonidazole.

C R, Wiltshire; P, Workman; J V, Watson; N M, Bleehen

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 1978

Data sources: Europe PubMed Central

Clinical studies with misonidazole.

descriptionPublicationkeyboard_double_arrow_right Article 18 Oct 1978 English Journal:The British journal of cancer. Supplement, volume 3 (issn: 0306-9443,

Copyright policy )

Authors: C R, Wiltshire; P, Workman; J V, Watson; N M, Bleehen;

pmid: 277246

pmc: PMC2149437

Clinical studies with misonidazole.

- Summary
- Subjects
- Metrics

Abstract

The preliminary details of a randomized clinical trial of misonidazole for the radiotherapy of Grades 3 and 4 cerebral astrocytoma are described. Plasma concentrations of misonidazole and its O-demethylated metabolite, determined by high-pressure liquid chromatography analysis, are reported for 8 patients with astrocytoma, 1 with carcinoma of the bronchus and 1 with carcinoma of the breast. In the latter case, tumour concentrations are also presented.

Keywords

Adult, Radiation-Sensitizing Agents, Random Allocation, Time Factors, Brain Neoplasms, Nitroimidazoles, Humans, Breast Neoplasms, Astrocytoma

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	38
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%